EichorEICHOR
Location: Santiago Synced from ClinicalTrials.gov · August 07, 2026

Clinical studies recruiting near Santiago

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

Observational Study Protocol: LIVER-R
Phase N/A · Research Site · AstraZeneca · NCT06252753A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Phase 3 · CHUS - Hospital Clinico Universitario · Eli Lilly and Company · NCT07218380A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart
Phase 3 · CON-38008, Santiago de Compostela, Galicia · Colorado Prevention Center · NCT06024746A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
Phase 2 · Investigational Site Number : 1520002 · Sanofi · NCT06867094Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Phase 3 · Centro de Estudios Clinicos SAGA · Daiichi Sankyo · NCT07022483High Intensity Interval Training and Insulin Sensitivity in Type 2 Diabetes
NA · Finis Terrae University · Finis Terrae University · NCT06688461A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line
Phase 3 · FALP-UIDO ( Site 2300) · Merck Sharp & Dohme LLC · NCT06136559Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.
Phase N/A · Hospital Clínico Universitario de Santiago ~ CHUS · Spanish Oncology Genito-Urinary Group · NCT06724159A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
Phase 2/Phase 3 · Biomedica Research Group ( Site 4201) · Merck Sharp & Dohme LLC · NCT07266831This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in
Phase 3 · Clínica Vespucio · Pfizer · NCT06758401Spanish Series of Patients Treated With the Radionuclide Lutetium177
Phase N/A · Hospital Clínico Universitario de Santiago · Sociedad Española de Medicina Nuclear e Imagen Molecular · NCT04949282A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
Phase 3 · Centro de estudios G y C-Site Number : 1520003 · Sanofi · NCT07190196A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Ag
Phase 3 · Complejo Hospitalario Universitario de Santiago (CHUS) - Hos · Travere Therapeutics, Inc. · NCT06247085A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit
Phase 1/Phase 2 · Bradfordhill · Bristol-Myers Squibb · NCT07291076The Effects of Price Reductions on Uptake of Preventive Dental Care
NA · Partnering clinic network · University of Chile · NCT07465952Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiov
Phase 3 · Biocinetic servicios medicos limitada · Amgen · NCT07037433A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintena
Phase 3 · FALP ( Site 0701) · Merck Sharp & Dohme LLC · NCT07216703A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
Phase 3 · Universidad San Sebastian - Providencia ( Site 0454) · Merck Sharp & Dohme LLC · NCT07044297Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management
Phase 2 · Centro Hospitalario Universitario de Santiago (CHUS) · SOLTI Breast Cancer Research Group · NCT07371585A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
Phase 2 · Research Site · AstraZeneca · NCT07276581Reduction of the Incidence of NAV in Neonatal Units (INBERNAV-Neo)
Phase N/A · Hospital Clínico Universitario de Santiago · Biobizkaia Health Research Institute · NCT07240038Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS
Phase 3 · FALP · Eli Lilly and Company · NCT06890598A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Phase 3 · Hosp. Clinico Univ. de Santiago · Janssen Research & Development, LLC · NCT07499232PRECAMA: Molecular Subtypes of Premenopausal Breast Cancer in Latin American Women
Phase N/A · INC · International Agency for Research on Cancer · NCT03144648Early Inflammatory Bowel Disease Progression
Phase N/A · Pontificia Universidad Catolica of Chile · Pontificia Universidad Catolica de Chile · NCT06756100Registry for Patients With Lipodystrophy
Phase N/A · Santiago de Compostela University · University of Ulm · NCT03553420A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic
Phase 3 · Research Site · AstraZeneca · NCT06868277A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in
Phase N/A · Complejo Hospitalario Universitario de Santiago (CHUS) · Hoffmann-La Roche · NCT07284121A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined
Phase 3 · Hospital Clinico Universidad de Los Andes · Regeneron Pharmaceuticals · NCT06091865A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
Phase 1 · Pontificia Universidad Catolica de Chile-CICUC ( Site 0103) · Merck Sharp & Dohme LLC · NCT07247110
Look up another city
Look up another condition
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.